http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-2.xsd
Confluence of the Heart and Kidney in Clinical Practice
XIX, 443 p. 83 illus., 57 illus. in color. online resource.
Extending from the outpatient management of cardiovascular and kidney disease, to hospital-based decision making in patients with cardio-renal disease and complex interfaces such as hemodialysis in patients with ventricular assist device support, this book serves as a single reference point for cardiology and nephrology clinicians and researchers dealing with the significant overlap areas between these two specialties. Chapters cover the physiology, biomarkers, therapeutic agents and full spectrum of these comorbidities and feature separate sections on cardiovascular and CKD evaluations, stratification of kidney transplant patients, lipid management in CKD, interventional strategies and hypertension. Leaders in cardiology, nephrology, hypertension and lipidology bring together the latest evidence with their collective clinical experience into this invaluable resource.This textbook is an essential resource for physicians and allied professionals practicing cardiology, nephrology, students and physician trainees, to deepen their understanding of this crucial field.
PART I: CARDIOVASCULAR DISEASE SPECTRUM IN CHRONIC KIDNEY DISEASE -- Chapter 1 Endothelial Dysfunction and Nitric Oxide: Albuminuria as a Central Marker -- Chapter 2 Vascular and Valvular Calcification in Chronic Kidney Disease: Pathogenesis and Clinical Outcomes -- Chapter 3 Sudden Cardiac Death in CKD and ESKD: Risk Factors, Mechanisms, and Therapeutic Strategies -- Chapter 4 Coronary Artery Disease in CKD: Traditional and Nontraditional Risk Factors, Diagnosis and Management -- Chapter 5 CKD Associated Cardiomyopathy: Molecular Mechanisms, Imaging Modalities, Disease Evolution and Interventions -- PART II: CHRONIC KIDNEY DISEASE AND CAD: TWO SIDES OF THE SAME COIN -- Chapter 6 CKD as CAD Equivalent: Inflammatory Milieu and Vascular Oxidative Stress -- Chapter 7 Phosphorus and Mortality: Do we have the Panacea? -- Chapter 8 Inhibition of the Renin Angiotensin System: How far have we come? -- Chapter 9 Vitamin D and its Role in CKD and CAD: A Novel Therapeutic Target -- Chapter 10 Association of Catalytic (Labile) Iron with Cardiovascular Morbidity and Mortality -- Chapter 11 Erythropoietin and its Cardiovascular Effects -- PART III: CARDIO-RENAL SYNDROME -- Chapter 12 Pathophysiology of the Cardio-Renal Syndromes Types 1-5: Updates from the Eleventh Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) -- Chapter 13 Hemodynamic Cross Talk in Cardiorenal Syndrome: Era of Biomarkers -- Chapter 14 Kidney Attack: Is NGAL Set to Take the Stage with Troponins? -- Chapter 15 Ultrafiltration Therapy in Decompensated Heart Failure -- Chapter 16 Bioimpedance Vectorial Analyses in Cardio Renal Syndrome -- Chapter 17 Novel Therapies for Acute Decompensated Heart Failure -- Chapter 18 Kidney Injury in Patients with Ventricular Assist Devices -- Chapter 19 Palliation with Dual Burden of Heart and Kidney Failure: An Underutilized Strategy -- PART IV: CARDIAC EVALUATION OF THE RENAL TRANSPLANT CANDIDATE -- Chapter 20 Screening Strategies for Coronary Artery Disease (CAD) in Candidates for Kidney Transplants -- Chapter 21 Cardiac Pre-Operative Evaluation as an Opportunity to Optimize Risk Factors in Kidney Transplant Candidates -- Chapter 22 Revascularization in Patients on the Renal Transplant List: When and What is Appropriate? -- Chapter 23 Pulmonary Hypertension in the Potential Kidney Transplant Recipient -- Chapter 24 Cardiac Surveillance whilst Listed for Renal Transplantation -- Chapter 25 Post Kidney Transplant Modification of Cardiovascular Risk -- Ch. 26 Cardiomyopathy in the Potential Kidney Transplant Candidate -- PART V: ANTICOAGULATION AND ANTIPLATELET THERAPY IN CKD -- Chapter 27 Anticoagulation in Patients with Atrial Fibrillation and Chronic Kidney Disease -- Chapter 28 Anticoagulation-Related Nephropathy: Tip of the Iceberg -- Chapter 29 Impact of Antiplatelet Therapy and Platelet Reactivity Testing on Cardiovascular Outcomes in Patients with Chronic Kidney Disease -- PART VI: INTERVENTIONAL STRATEGIES IN CARDIOVASCULAR DISEASE IN CKD -- Chapter 30 Revascularization Strategies in Chronic Kidney Disease: Percutaneous Coronary Intervention vs. Coronary Artery Bypass Graft Surgery -- Chapter 31 Revascularization Strategies in CKD: Anti-Platelet Therapy, Stent Type, Timing, and Complications of PCI -- Chapter 32 Peripheral Arterial Disease in CKD: Disease Burden, Outcomes and Interventional Strategies -- Chapter 33 Contrast Induced Nephropathy -- Chapter 34 Acute Kidney Injury after Cardiac Surgery -- PART VII: THE CARDIORENOMETABOLIC SPECTRUM -- Chapter 35 Dyslipidemias in CKD and ESKD: Outcomes and Management -- Chapter 36 The Cardiac Impact of Atherosclerotic Renovascular Disease (ARVD) -- Chapter 37 Preeclampsia: A Mirror into Future Cardiovascular and Renal Health -- Chapter 38 Obstructive Sleep Apnea: A Unifying Link between Cardiovascular and Renal Disease -- PART VIII: DILEMMAS IN HYPERTENSION -- Chapter 39 Chronic Kidney Disease and BP Goals -- Chapter 40 Renal Artery Stenosis: Diagnosis and Management -- Chapter 41 Renal Denervation: Current Opinions and Practice.
edited by Janani Rangaswami, Edgar V. Lerma, Claudio Ronco.
Plný text je dostupný pouze z IP adres počítačů Univerzity Tomáše Bati ve Zlíně nebo vzdáleným přístupem pro zaměstnance a studenty